Bayer's Legal and Financial Fate Hinges on Supreme Court Hearing

Bayer faces a pivotal US Supreme Court hearing on glyphosate lawsuits. A ruling could limit 65,000 pending cases or prolong legal uncertainty, as the firm balances stable drug sales against heavy litigation costs.

The German pharmaceutical and agricultural giant Bayer faces a defining fortnight, with a pivotal US Supreme Court hearing on April 27th poised to fundamentally reshape its multi-billion dollar legal liabilities. The outcome could either stem a tide of litigation or leave the company mired in uncertainty for years to come.

At the heart of the case, Durnell v. Monsanto, is a critical legal argument: whether federal law, specifically the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), preempts state-level warning label lawsuits concerning the herbicide glyphosate. The US Environmental Protection Agency has not mandated a cancer warning on Roundup labels, a position Bayer contends should shield it from such claims. The Supreme Court agreed to hear the case precisely due to a split in lower court rulings, with two appeals courts rejecting Bayer's argument and a third, the Third Circuit Court of Appeals, siding with the company.

The stakes are monumental. A favorable ruling, expected by June 2026, could dramatically limit the flood of approximately 65,000 pending lawsuits and provide structural relief from the legal cloud that has hung over Bayer since its $63 billion acquisition of Monsanto in 2018. To date, the company has paid out more than $11 billion in settlements and judgments related to over 100,000 claims. The legal landscape is further complicated by 18 amicus briefs filed with the Court, including submissions from the attorneys general of Texas, Florida, and Ohio opposing Bayer's position.

Parallel to these proceedings, a separate $7.25 billion settlement in the case King v. Monsanto, announced in February 2026 to address current and future non-Hodgkin lymphoma claims, received preliminary approval from Judge Timothy J. Boyer in March.

Amid this legal drama, the company's operational performance tells a more stable story. Bayer recently reaffirmed its 2026 targets, with its pharmaceuticals division acting as the primary engine. The kidney and heart drug Kerendia, which recently gained an expanded EU approval for heart failure, saw currency-adjusted growth of over 88%. Management has set a long-term peak sales target exceeding €3 billion for the medication. Furthermore, the prostate cancer drug Nubeqa is gaining traction, helping to offset revenue pressure from the patent expiry of blockbuster Xarelto.

Financially, the picture is mixed. The company forecasts an adjusted EBITDA before special items of €9.6 to €10.1 billion for 2026, compared to €9.669 billion the previous year. Pharmaceuticals COO Sebastian Guth told Reuters that US pharmaceutical tariffs, capped at 15% under an EU-US trade agreement, do not warrant a guidance adjustment. However, the balance sheet remains under strain. Management anticipates a negative free cash flow for 2026 due to ongoing litigation payouts, even as net financial debt decreased by 8.5% year-over-year to approximately €29.8 billion at the end of 2025.

This tension between operational steadiness and legal overhang is reflected in shifting analyst sentiment. UBS reiterated its Buy rating with a €52 price target, implying a 28% upside from the current share price of €40.63. In a more notable shift, DZ Bank upgraded its rating from Sell to Hold and raised its target from €42 to €44, citing improved calculability of legal risks.

Shareholders will gather for the Annual General Meeting on April 24th, where they will vote on a dividend of €0.11 per share and the election of two new supervisory board members. Yet, the true focus for investors and management alike remains fixed on Washington D.C. three days later. CEO Bill Anderson views the Supreme Court's acceptance of the case as a decisive step toward regulatory clarity. Company executives see 2027 as a potential turning point for financial recovery, a prospect that rests almost entirely on the justices' impending decision.